Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation

Jhih-Hang Jiang, Md Saruar Bhuiyan, Hsin-Hui Shen, David R Cameron, Thusitha W T Rupasinghe, Chun-Ming Wu, Anton P Le Brun, Xenia Kostoulias, Carmen Domene, Alex J Fulcher, Malcolm J McConville, Benjamin P Howden, Graham J Lieschke, Anton Y Peleg

Research output: Contribution to journalArticle

1 Citation (Scopus)
2 Downloads (Pure)

Abstract

Staphylococcus aureus is a notorious human bacterial pathogen with considerable capacity to develop antibiotic resistance. We have observed that human infections caused by highly drug-resistant S. aureus are more prolonged, complicated, and difficult to eradicate. Here we describe a metabolic adaptation strategy used by clinical S. aureus strains that leads to resistance to the last-line antibiotic, daptomycin, and simultaneously affects host innate immunity. This response was characterized by a change in anionic membrane phospholipid composition induced by point mutations in the phospholipid biosynthesis gene, cls2, encoding cardiolipin synthase. Single cls2 point mutations were sufficient for daptomycin resistance, antibiotic treatment failure, and persistent infection. These phenotypes were mediated by enhanced cardiolipin biosynthesis, leading to increased bacterial membrane cardiolipin and reduced phosphatidylglycerol. The changes in membrane phospholipid profile led to modifications in membrane structure that impaired daptomycin penetration and membrane disruption. The cls2 point mutations also allowed S. aureus to evade neutrophil chemotaxis, mediated by the reduction in bacterial membrane phosphatidylglycerol, a previously undescribed bacterial-driven chemoattractant. Together, these data illustrate a metabolic strategy used by S. aureus to circumvent antibiotic and immune attack and provide crucial insights into membrane-based therapeutic targeting of this troublesome pathogen.

Original languageEnglish
Pages (from-to)3722-3727
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number9
Early online date11 Feb 2019
DOIs
Publication statusPublished - 26 Feb 2019

Cite this

Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation. / Jiang, Jhih-Hang; Bhuiyan, Md Saruar; Shen, Hsin-Hui; Cameron, David R; Rupasinghe, Thusitha W T; Wu, Chun-Ming; Le Brun, Anton P; Kostoulias, Xenia; Domene, Carmen; Fulcher, Alex J; McConville, Malcolm J; Howden, Benjamin P; Lieschke, Graham J; Peleg, Anton Y.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 9, 26.02.2019, p. 3722-3727.

Research output: Contribution to journalArticle

Jiang, J-H, Bhuiyan, MS, Shen, H-H, Cameron, DR, Rupasinghe, TWT, Wu, C-M, Le Brun, AP, Kostoulias, X, Domene, C, Fulcher, AJ, McConville, MJ, Howden, BP, Lieschke, GJ & Peleg, AY 2019, 'Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation', Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 9, pp. 3722-3727. https://doi.org/10.1073/pnas.1812066116
Jiang, Jhih-Hang ; Bhuiyan, Md Saruar ; Shen, Hsin-Hui ; Cameron, David R ; Rupasinghe, Thusitha W T ; Wu, Chun-Ming ; Le Brun, Anton P ; Kostoulias, Xenia ; Domene, Carmen ; Fulcher, Alex J ; McConville, Malcolm J ; Howden, Benjamin P ; Lieschke, Graham J ; Peleg, Anton Y. / Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 9. pp. 3722-3727.
@article{c4f0ea7df1b24be7aa160aff6343a730,
title = "Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation",
abstract = "Staphylococcus aureus is a notorious human bacterial pathogen with considerable capacity to develop antibiotic resistance. We have observed that human infections caused by highly drug-resistant S. aureus are more prolonged, complicated, and difficult to eradicate. Here we describe a metabolic adaptation strategy used by clinical S. aureus strains that leads to resistance to the last-line antibiotic, daptomycin, and simultaneously affects host innate immunity. This response was characterized by a change in anionic membrane phospholipid composition induced by point mutations in the phospholipid biosynthesis gene, cls2, encoding cardiolipin synthase. Single cls2 point mutations were sufficient for daptomycin resistance, antibiotic treatment failure, and persistent infection. These phenotypes were mediated by enhanced cardiolipin biosynthesis, leading to increased bacterial membrane cardiolipin and reduced phosphatidylglycerol. The changes in membrane phospholipid profile led to modifications in membrane structure that impaired daptomycin penetration and membrane disruption. The cls2 point mutations also allowed S. aureus to evade neutrophil chemotaxis, mediated by the reduction in bacterial membrane phosphatidylglycerol, a previously undescribed bacterial-driven chemoattractant. Together, these data illustrate a metabolic strategy used by S. aureus to circumvent antibiotic and immune attack and provide crucial insights into membrane-based therapeutic targeting of this troublesome pathogen.",
author = "Jhih-Hang Jiang and Bhuiyan, {Md Saruar} and Hsin-Hui Shen and Cameron, {David R} and Rupasinghe, {Thusitha W T} and Chun-Ming Wu and {Le Brun}, {Anton P} and Xenia Kostoulias and Carmen Domene and Fulcher, {Alex J} and McConville, {Malcolm J} and Howden, {Benjamin P} and Lieschke, {Graham J} and Peleg, {Anton Y}",
year = "2019",
month = "2",
day = "26",
doi = "10.1073/pnas.1812066116",
language = "English",
volume = "116",
pages = "3722--3727",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "9",

}

TY - JOUR

T1 - Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation

AU - Jiang, Jhih-Hang

AU - Bhuiyan, Md Saruar

AU - Shen, Hsin-Hui

AU - Cameron, David R

AU - Rupasinghe, Thusitha W T

AU - Wu, Chun-Ming

AU - Le Brun, Anton P

AU - Kostoulias, Xenia

AU - Domene, Carmen

AU - Fulcher, Alex J

AU - McConville, Malcolm J

AU - Howden, Benjamin P

AU - Lieschke, Graham J

AU - Peleg, Anton Y

PY - 2019/2/26

Y1 - 2019/2/26

N2 - Staphylococcus aureus is a notorious human bacterial pathogen with considerable capacity to develop antibiotic resistance. We have observed that human infections caused by highly drug-resistant S. aureus are more prolonged, complicated, and difficult to eradicate. Here we describe a metabolic adaptation strategy used by clinical S. aureus strains that leads to resistance to the last-line antibiotic, daptomycin, and simultaneously affects host innate immunity. This response was characterized by a change in anionic membrane phospholipid composition induced by point mutations in the phospholipid biosynthesis gene, cls2, encoding cardiolipin synthase. Single cls2 point mutations were sufficient for daptomycin resistance, antibiotic treatment failure, and persistent infection. These phenotypes were mediated by enhanced cardiolipin biosynthesis, leading to increased bacterial membrane cardiolipin and reduced phosphatidylglycerol. The changes in membrane phospholipid profile led to modifications in membrane structure that impaired daptomycin penetration and membrane disruption. The cls2 point mutations also allowed S. aureus to evade neutrophil chemotaxis, mediated by the reduction in bacterial membrane phosphatidylglycerol, a previously undescribed bacterial-driven chemoattractant. Together, these data illustrate a metabolic strategy used by S. aureus to circumvent antibiotic and immune attack and provide crucial insights into membrane-based therapeutic targeting of this troublesome pathogen.

AB - Staphylococcus aureus is a notorious human bacterial pathogen with considerable capacity to develop antibiotic resistance. We have observed that human infections caused by highly drug-resistant S. aureus are more prolonged, complicated, and difficult to eradicate. Here we describe a metabolic adaptation strategy used by clinical S. aureus strains that leads to resistance to the last-line antibiotic, daptomycin, and simultaneously affects host innate immunity. This response was characterized by a change in anionic membrane phospholipid composition induced by point mutations in the phospholipid biosynthesis gene, cls2, encoding cardiolipin synthase. Single cls2 point mutations were sufficient for daptomycin resistance, antibiotic treatment failure, and persistent infection. These phenotypes were mediated by enhanced cardiolipin biosynthesis, leading to increased bacterial membrane cardiolipin and reduced phosphatidylglycerol. The changes in membrane phospholipid profile led to modifications in membrane structure that impaired daptomycin penetration and membrane disruption. The cls2 point mutations also allowed S. aureus to evade neutrophil chemotaxis, mediated by the reduction in bacterial membrane phosphatidylglycerol, a previously undescribed bacterial-driven chemoattractant. Together, these data illustrate a metabolic strategy used by S. aureus to circumvent antibiotic and immune attack and provide crucial insights into membrane-based therapeutic targeting of this troublesome pathogen.

U2 - 10.1073/pnas.1812066116

DO - 10.1073/pnas.1812066116

M3 - Article

VL - 116

SP - 3722

EP - 3727

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 9

ER -